GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenetic Biosciences Inc (NAS:XBIO) » Definitions » Operating Margin %

Xenetic Biosciences (Xenetic Biosciences) Operating Margin % : -248.14% (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Xenetic Biosciences Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Xenetic Biosciences's Operating Income for the three months ended in Mar. 2024 was $-1.27 Mil. Xenetic Biosciences's Revenue for the three months ended in Mar. 2024 was $0.51 Mil. Therefore, Xenetic Biosciences's Operating Margin % for the quarter that ended in Mar. 2024 was -248.14%.

The historical rank and industry rank for Xenetic Biosciences's Operating Margin % or its related term are showing as below:

XBIO' s Operating Margin % Range Over the Past 10 Years
Min: -56488.24   Med: -495   Max: -47.05
Current: -199.14


XBIO's Operating Margin % is ranked worse than
52.19% of 1027 companies
in the Biotechnology industry
Industry Median: -161.26 vs XBIO: -199.14

Xenetic Biosciences's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Xenetic Biosciences's Operating Income for the three months ended in Mar. 2024 was $-1.27 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.87 Mil.


Xenetic Biosciences Operating Margin % Historical Data

The historical data trend for Xenetic Biosciences's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenetic Biosciences Operating Margin % Chart

Xenetic Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -56,488.24 -1,074.37 -495.00 -393.56 -177.80

Xenetic Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -150.99 -184.02 -187.73 -186.90 -248.14

Competitive Comparison of Xenetic Biosciences's Operating Margin %

For the Biotechnology subindustry, Xenetic Biosciences's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenetic Biosciences's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Xenetic Biosciences's Operating Margin % falls into.



Xenetic Biosciences Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Xenetic Biosciences's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-4.516 / 2.54
=-177.80 %

Xenetic Biosciences's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-1.268 / 0.511
=-248.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xenetic Biosciences  (NAS:XBIO) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Xenetic Biosciences Operating Margin % Related Terms

Thank you for viewing the detailed overview of Xenetic Biosciences's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Xenetic Biosciences (Xenetic Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
945 Concord Street, Framingham, MA, USA, 01701
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Executives
Grigory G. Borisenko director 40 SPEEN STREET, SUITE 102, FRAMINGHAM MA 01701
Alexey Andreevich Vinogradov director C/O XENETIC BIOSCIENCES, INC., 40 SPEEN STREET, FRAMINGHAM MA 01701
Adam Logal director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
James Eric Callaway director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Dmitry Genkin director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
James F Parslow officer: Chief Financial Officer C/O XENETIC BIOSCIENCES, INC., 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Curtis Lockshin officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Benz Edward J. Jr director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Roger D. Kornberg director 345 WALSH ROAD, ATHERTON CA 94027
Darlene M Deptula-hicks director C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Jeffrey F Eisenberg director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Firdaus J. Dastoor director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Michael Scott Maguire director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Roman Knyazev director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Pharmsynthez Pjsc 10 percent owner 25 LITER KRASNOVO KURSANTA STREET, ST. PETERSBURG 1Z 197110

Xenetic Biosciences (Xenetic Biosciences) Headlines

From GuruFocus